ClinicalTrials.gg
CompletedNCT05232825Ocarina IIUpdated Aug 11, 2026Results posted

A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis

A Phase 3 interventional study of Ocrelizumab IV and Ocrelizumab SC in Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis, sponsored by Hoffmann-La Roche. Completed at 37 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
236
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive — 2 open to participants now, 6 under way, 4 of them phase 3. ocrelizumab · Multiple Sclerosis, Chronic Progressive.

Enrollment
5th of 10
236 · median 184
Started
2022
the only one that year
Phase 3
7 of 10
1 open now
Registered
8th of 10
by date
Lead sponsor
6 of 10
Hoffmann-La Roche

Among the 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive, this one is the 5th largest by enrollment, is the only one that started in 2022, is one of 7 in phase 3, and was the 8th registered.

Multiple Sclerosis, Chronic Progressive

245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.

Browse Multiple Sclerosis, Chronic Progressive studies →

Open to participants now

2 of the 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ocrelizumab

ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 39 Multiple Sclerosis, Chronic Progressive studies recruiting now, 7 (18%) set no upper age limit and 26 (67%) stop at 75 or younger; none take children under 18; 6 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing ocrelizumab in Multiple Sclerosis, Chronic Progressive, or all of them as a file.
02

Study summary

This study will evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and radiological and clinical effects of subcutaneous (SC) administration of ocrelizumab compared with the intravenous (IV) infusion of ocrelizumab in patients with either relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS).

03

Conditions studied

  • Relapsing Multiple Sclerosis
  • Primary Progressive Multiple Sclerosis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of PPMS or RMS according to the revised McDonald 2017 criteria (Thompson et al. 2018)
  • EDSS score, 0-6.5, inclusive, at screening
  • Neurological stability for ≥30 days prior to both screening and baseline
  • Disease duration from onset of MS symptoms of less than 15 years for patients with EDSS score \<2.0 at screening
  • For females participants, without may be enrolled if , unless receiving a hormonal therapy for menopause or if surgically sterile
  • For females of , agreement to remain abstinent or use adequate methods

Exclusion criteria

Exclusion Criteria:

  • Any known or suspected active infection at screening or baseline (except nailbed infections), or any major episode of infection requiring hospitalization or treatment with IV anti microbials within 8 weeks prior to and during screening or treatment with oral anti microbials within 2 weeks prior to and during screening
  • History of confirmed or suspected progressive multifocal leukoencephalopathy (PML)
  • History of cancer, including hematologic and solid tumors, within 10 years of screening
  • state
  • Receipt of a within 6 weeks prior to randomization Influenza vaccination is permitted if the inactivated vaccine formulation is administered
  • Inability to complete an MRI or to gadolinium administration
  • Contraindications to mandatory premedications for IRRs, including closed-angle glaucoma for antihistamines
  • Known presence of other neurologic disorders
  • Any concomitant disease that may require chronic treatment with systemic or immunosuppressants during the course of the study
  • Significant, uncontrolled disease, such as cardiovascular, pulmonary, renal, hepatic, endocrine or gastrointestinal, or any other significant disease that may preclude patient from participating in the study
  • History of or currently active primary or secondary (non-drug-related) immunodeficiency
  • Pregnant or breastfeeding, or intending to become pregnant during the study and 6 or 12 months
  • Lack of peripheral venous access
  • History of alcohol or other drug abuse within 12 months prior to screening
  • Treatment with any agent within 24 weeks prior to screening or 5 half-lives of the investigational drug (whichever is longer), or treatment with any experimental procedure for MS (e.g., treatment for chronic cerebrospinal venous insufficiency)
  • Participants who have previously received anti-CD20s if the last treatment was less than 2 years before screening, and/or if B-cell count is below lower limit of normal, and/or the discontinuation of the treatment was due to safety reasons or lack of efficacy
  • Previous treatment with cladribine, atacicept, and alemtuzumab
  • Previous treatment with fingolimod, siponimod, ponesimod, or ozanimod within 6 weeks of baseline
  • Previous treatment with interferons beta (1a or 1b), or glatiramer acetate within 2 weeks of baseline
  • Previous treatment with natalizumab within 4.5 months of baseline
  • Treatment with mitoxantrone within 2 years prior to baseline visit or evidence of cardiotoxicity following mitoxantrone use or a cumulative lifetime dose of more than 60 mg/m2
  • Previous treatment with any other immunomodulatory or immunosuppressive medication not already listed above without appropriate as described in the applicable local label.
  • If the washout requirements are not described in the applicable local label, then the wash out period must be 5 times the half-life of the medication. The PD effects of the previous medication must also be considered when determining the required time for washout.
  • Any previous treatment with bone marrow transplantation and hematopoietic stem cell transplantation
  • Any previous history of transplantation or anti-rejection therapy
  • Treatment with IV Ig or plasmapheresis within 12 weeks prior to randomization
  • Systemic corticosteroid therapy within 4 weeks prior to screening
  • Positive screening tests for active, latent, or inadequately treated
  • Sensitivity or intolerance to any ingredient (including ) of ocrelizumab
  • Any additional exclusionary criterion as per ocrelizumab (Ocrevus®) local label, if more stringent than the above
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
236 participants (actual)

Study arms

  • Active comparator
    Ocrelizumab: Intravenous (IV) formulation

    Participants will receive the first dose of ocrelizumab IV as two IV infusions given 14 days apart. The subsequent doses of study drug will be administered as SC injections. A minimum of 22 weeks should be kept between SC doses. Participants will undergo 96 weeks of study treatment.

    Drug: Ocrelizumab IV · Drug: Methylprednisolone IV · Drug: Diphenhydramine IV

  • Experimental
    Ocrelizumab: Subcutaneous (SC) formulation

    Participants will receive the first dose of ocrelizumab SC as one SC injection at a dose which is expected to result in non-inferior exposure to ocrelizumab IV. The subsequent doses of study drug will be administered as SC injections. A minimum of 22 weeks should be kept between the first and second SC doses, and between subsequent SC doses. Participants will undergo 96 weeks of study treatment.

    Drug: Ocrelizumab SC · Drug: Dexamethasone given orally · Drug: Desloratadine given orally

Interventions

  • IV Injection

    Also known as: RO4964913

  • SC Injection

    Also known as: RO4964913

  • Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab infusion

  • Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab infusion

  • DrugDexamethasone given orally

    Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab injection

  • DrugDesloratadine given orally

    Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab injection

06

What researchers measure

Primary outcomes

  1. Serum Ocrelizumab Area Under the Concentration-Time Curve Over the First 12 Weeks (AUCW1-12) After SC Administration

    Time frame: Day 1 Week 1 to Week 12

Secondary outcomes

  1. Maximum Serum Concentration (Cmax) of Ocrelizumab SC

    Time frame: Day 1 Week 1 to Week 24

  2. Rate of Gadolinium-enhancing Lesions on T1-weighted (T1Gd+) Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) at Weeks 8 and 24

    Radiologic evaluation for the total number of T1Gd+ lesions was performed using a standardized MRI at Weeks 8 and 24 to monitor central nervous system (CNS) lesions in participants with MS. Estimand variable (adjusted lesion rate) was modeled by a negative binomial regression that included treatment variable \& was adjusted for covariates: baseline T1Gd+ lesion (present or not), geographical region (United States of America vs. Rest of the world). EE = Efficacy-evaluable.

    Time frame: At Weeks 8 and 24

  3. Rate of New or Enlarging T2 Lesions as Detected by Brain MRI at Weeks 12 and 24

    Radiologic evaluation for the new or enlarging T2 lesions was performed using a standardized MRI at Weeks 12 and 24 to monitor CNS lesions in participants with MS. Estimand variable (adjusted lesion rate) was modeled by a negative binomial regression that included treatment variable \& was adjusted for covariates: baseline T2 lesion count, geographical region (United States of America vs. Rest of the world).

    Time frame: At Weeks 12 and 24

  4. Number of Participants With Adverse Events (AEs)

    An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

    Time frame: From initiation of study drug until 24 weeks after the final dose of study drug (up to 138.1 weeks)

  5. Number of Participants With Anti-drug Antibodies (ADAs) to Ocrelizumab After SC or IV Administration

    Participants who received ocrelizumab were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following ocrelizumab exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the titer of the baseline sample (treatment-enhanced ADA response). Participants with a positive post-baseline sample has been reported here.

    Time frame: Up to 138.1 weeks

  6. Number of Participants With ADAs to rHuPH20 After Ocrelizumab SC Administration

    Ocrelizumab SC formulation is co-formulated with rHuPH20 at a concentration of 1000 units per milliliter (U/mL). Participants who received ocrelizumab SC were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following ocrelizumab SC exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the titer of the baseline sample (treatment-enhanced ADA response). Participants with a positive post-baseline sample has been reported here.

    Time frame: Up to 138.1 weeks

  7. Percentage of Participants Who Achieved CD19+ B Cell Level of ≤5 Cells/Microliters (µL) at Weeks 12, 24, 48, and/or 96

    B-cells were assessed in fresh whole blood using flow cytometry. Percentages have been rounded off.

    Time frame: At Weeks 12, 24, 48, and 96

07

Results

Posted Aug 11, 2026

Participant flow

A total of 236 participants with primary progressive multiple sclerosis (PPMS) or relapsing multiple sclerosis (RMS) took part in the study at 37 investigative sites across 8 countries from 03 May 2022 to 06 June 2025.

Controlled Period
Participant flow — Controlled Period
MilestoneOcrelizumab IVOcrelizumab SC
Started118118
Completed115118
Not completed30
Withdrew: Discontinued and entered sfu period20
Withdrew: Physician decision10
Ocrelizumab SC Treatment Period
Participant flow — Ocrelizumab SC Treatment Period
MilestoneOcrelizumab IVOcrelizumab SC
Started115118
Completed109110
Not completed68
Withdrew: Discontinued and entered sfu period25
Withdrew: Withdrawal by subject33
Withdrew: Adverse event10
SFU Period
Participant flow — SFU Period
MilestoneOcrelizumab IVOcrelizumab SC
Started113115
Completed112115
Not completed10
Withdrew: Lost to follow-up10

Outcome measures

PrimarySerum Ocrelizumab Area Under the Concentration-Time Curve Over the First 12 Weeks (AUCW1-12) After SC Administration
Time frame:
Day 1 Week 1 to Week 12
Reported as:
Mean · micrograms/milliliters*day (µg/mL*day)
Serum Ocrelizumab Area Under the Concentration-Time Curve Over the First 12 Weeks (AUCW1-12) After SC Administration
micrograms/milliliters*day (µg/mL*day)Ocrelizumab IVOcrelizumab SC
Serum Ocrelizumab Area Under the Concentration-Time Curve Over the First 12 Weeks (AUCW1-12) After SC Administration2750 ± 7963500 ± 914
Statistical analysis
  • Ocrelizumab IV vs Ocrelizumab SC · Geometric mean ratio: 1.2851 · 90% CI 1.2258 to 1.3473
SecondaryMaximum Serum Concentration (Cmax) of Ocrelizumab SC
Time frame:
Day 1 Week 1 to Week 24
Reported as:
Mean · micrograms/milliliters (µg/mL)
Maximum Serum Concentration (Cmax) of Ocrelizumab SC
micrograms/milliliters (µg/mL)Ocrelizumab IVOcrelizumab SC
Maximum Serum Concentration (Cmax) of Ocrelizumab SC137 ± 29.5132 ± 31.9
SecondaryRate of Gadolinium-enhancing Lesions on T1-weighted (T1Gd+) Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) at Weeks 8 and 24

Radiologic evaluation for the total number of T1Gd+ lesions was performed using a standardized MRI at Weeks 8 and 24 to monitor central nervous system (CNS) lesions in participants with MS. Estimand variable (adjusted lesion rate) was modeled by a negative binomial regression that included treatment variable \& was adjusted for covariates: baseline T1Gd+ lesion (present or not), geographical region (United States of America vs. Rest of the world). EE = Efficacy-evaluable.

Time frame:
At Weeks 8 and 24
Reported as:
Least squares mean · lesions per participant
Rate of Gadolinium-enhancing Lesions on T1-weighted (T1Gd+) Lesions as Detected by Brain Magnetic Resonance Imaging (MRI) at Weeks 8 and 24
lesions per participantOcrelizumab IVOcrelizumab SC
At Week 80.060 (0.020 to 0.150)0.060 (0.020 to 0.140)
At Week 240.000 (0.000 to NA)0.000 (0.000 to NA)
SecondaryRate of New or Enlarging T2 Lesions as Detected by Brain MRI at Weeks 12 and 24

Radiologic evaluation for the new or enlarging T2 lesions was performed using a standardized MRI at Weeks 12 and 24 to monitor CNS lesions in participants with MS. Estimand variable (adjusted lesion rate) was modeled by a negative binomial regression that included treatment variable \& was adjusted for covariates: baseline T2 lesion count, geographical region (United States of America vs. Rest of the world).

Time frame:
At Weeks 12 and 24
Reported as:
Least squares mean · lesions per participant
Rate of New or Enlarging T2 Lesions as Detected by Brain MRI at Weeks 12 and 24
lesions per participantOcrelizumab IVOcrelizumab SC
At Week 120.050 (0.010 to 0.170)0.020 (0.000 to 0.100)
At Week 240.000 (0.000 to 0.000)0.000 (0.000 to 0.010)
SecondaryNumber of Participants With Adverse Events (AEs)

An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Time frame:
From initiation of study drug until 24 weeks after the final dose of study drug (up to 138.1 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsOcrelizumab IVOcrelizumab SC
Number of Participants With Adverse Events (AEs)101111
SecondaryNumber of Participants With Anti-drug Antibodies (ADAs) to Ocrelizumab After SC or IV Administration

Participants who received ocrelizumab were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following ocrelizumab exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the titer of the baseline sample (treatment-enhanced ADA response). Participants with a positive post-baseline sample has been reported here.

Time frame:
Up to 138.1 weeks
Reported as:
Count of participants · Participants
Number of Participants With Anti-drug Antibodies (ADAs) to Ocrelizumab After SC or IV Administration
ParticipantsOcrelizumab IVOcrelizumab SC
Number of Participants With Anti-drug Antibodies (ADAs) to Ocrelizumab After SC or IV Administration00
SecondaryNumber of Participants With ADAs to rHuPH20 After Ocrelizumab SC Administration

Ocrelizumab SC formulation is co-formulated with rHuPH20 at a concentration of 1000 units per milliliter (U/mL). Participants who received ocrelizumab SC were considered to be treatment-emergent ADA-positive if they were ADA-negative or had missing data at baseline but developed an ADA response following ocrelizumab SC exposure (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 0.60 titer units (t.u.) greater than the titer of the baseline sample (treatment-enhanced ADA response). Participants with a positive post-baseline sample has been reported here.

Time frame:
Up to 138.1 weeks
Reported as:
Count of participants · Participants
Number of Participants With ADAs to rHuPH20 After Ocrelizumab SC Administration
ParticipantsOcrelizumab IVOcrelizumab SC
Number of Participants With ADAs to rHuPH20 After Ocrelizumab SC Administration14
SecondaryPercentage of Participants Who Achieved CD19+ B Cell Level of ≤5 Cells/Microliters (µL) at Weeks 12, 24, 48, and/or 96

B-cells were assessed in fresh whole blood using flow cytometry. Percentages have been rounded off.

Time frame:
At Weeks 12, 24, 48, and 96
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved CD19+ B Cell Level of ≤5 Cells/Microliters (µL) at Weeks 12, 24, 48, and/or 96
percentage of participantsOcrelizumab IVOcrelizumab SC
At Week 1298.398.3
At Week 2478.974.6
At Week 4892.086.0
At Week 9692.590.7

Adverse events

Collected over From initiation of study drug until 24 weeks after the final dose of study drug (up to 138.1 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ocrelizumab IV0/118 (0%)9/118 (7.6%)86/118 (72.9%)
Ocrelizumab SC0/118 (0%)7/118 (5.9%)99/118 (83.9%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventOcrelizumab IVOcrelizumab SC
Multiple sclerosis pseudo relapseNervous system disorders0/1182/118
Eye painEye disorders0/1181/118
AppendicitisInfections and infestations1/1180/118
Cellulitis staphylococcalInfections and infestations1/1180/118
PneumoniaInfections and infestations1/1180/118
Subcutaneous abscessInfections and infestations1/1180/118
Upper respiratory tract infectionInfections and infestations1/1180/118
Diabetes mellitusMetabolism and nutrition disorders1/1180/118
Multiple sclerosis relapseNervous system disorders0/1181/118
AnxietyPsychiatric disorders0/1181/118
Most frequent other events
Showing 10 of 18
Most frequent other events
EventOcrelizumab IVOcrelizumab SC
Injection related reactionInjury, poisoning and procedural complications55/11874/118
Infusion related reactionInjury, poisoning and procedural complications20/1180/118
COVID-19Infections and infestations12/11819/118
Upper respiratory tract infectionInfections and infestations18/11818/118
Urinary tract infectionInfections and infestations12/11815/118
HeadacheNervous system disorders6/11813/118
NasopharyngitisInfections and infestations6/11811/118
BronchitisInfections and infestations9/11810/118
RhinitisInfections and infestations1/11810/118
Oral herpesInfections and infestations1/1187/118

Baseline characteristics

Safety evaluable (SE) - all set included all randomized participants who received at least one infusion (partial or complete) or injection (partial or complete) of study drug, grouped according to treatment received at first exposure.

Age, Continuous
Age, Continuous(years)Ocrelizumab IVOcrelizumab SCTotal
Mean40.0 ± 11.939.9 ± 11.439.9 ± 11.6
Sex: Female, Male
Sex: Female, Male(Participants)Ocrelizumab IVOcrelizumab SCTotal
Female7077147
Male484189
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ocrelizumab IVOcrelizumab SCTotal
Hispanic or Latino8816
Not Hispanic or Latino9394187
Unknown or Not Reported171633
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ocrelizumab IVOcrelizumab SCTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander101
Black or African American178
White109102211
More than one race134
Unknown or Not Reported5611
08

Study locations

37 sites
  • Neurology Associates PA
    Maitland, Florida 32751, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Memorial Healthcare Institute for Neurosciences and Multiple Sclerosis
    Owosso, Michigan 48867, United States
  • UC Health Neurology
    Dayton, Ohio 45417, United States
  • Premier Neurology
    Greenville, South Carolina 29605, United States
  • Neurology Clinic PC
    Cordova, Tennessee 38018, United States
  • CEDOES - Diagnóstico e Pesquisa
    Vitória, Espírito Santo 29055-450, Brazil
  • Clinica Amo Assistencia Medica Em Oncologia
    Salvador, Estado de Bahia 41950640, Brazil
  • Fakultni nemocnice u sv. Anny
    Brno, 656 91, Czechia
  • Charles University, Medical faculty, Hradec Kralove
    Hradec Králové, 500 05, Czechia
  • Nemocnice Jihlava
    Jihlava, 58633, Czechia
  • Fakultni nemocnice Ostrava
    Ostrava-Poruba, 708 52, Czechia
  • Pardubicka Krajska Nemocnice
    Pardubice, 532 03, Czechia
  • Fakultni poliklinika VFN
    Prague, 128 08, Czechia
  • Fakultni nemocnice Motol
    Prague, 150 06, Czechia
  • Krajska zdravotni a.s Nemocnice Teplice o.z.
    Teplice, 415 01, Czechia
  • Policlinico Tor Vergata Dip. Neuroscienze-Clinica Neurologica-UOSD Sclerosi Multipla
    Rome, Lazio 00133, Italy
  • Azienda Ospedaliera Sant'Andrea
    Rome, Lazio 00189, Italy
  • Ospedale Civile di Montichiari
    Montichiari, Lombardy 25018, Italy
  • IRCCS Istituto Neurologico Neuromed
    Pozzilli, Molise 86077, Italy
  • Optimal Clinical Trials
    Auckland, 1010, New Zealand
  • Hawkes Bay Hospital
    Hastings, 4120, New Zealand
  • Neurocentrum Bydgoszcz sp. z o.o
    Bydgoszcz, 85-796, Poland
  • Care Clinic
    Katowice, 40-568, Poland
  • Centrum Neurologii Krzysztof Selmaj
    Lodz, 90-324, Poland
  • Przychodnia EuroMediCare
    Wroc?aw, 50-220, Poland
  • Hospital Universitario Puerta de Hierro Majadahonda
    Majadahonda, Madrid 28222, Spain
  • Hospital Universitario Virgen Macarena
    Seville, Sevilla 41071, Spain
  • Complejo Hospitalario Nuestra Señora de la Candelaria
    Santa Cruz de Tenerife, Tenerife 38010, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Universitario Reina Sofia
    Córdoba, 14011, Spain
  • Bakirkoy State Mental Hospital
    Istanbul, 34000, Turkey (Türkiye)
  • Istanbul Universitesi - Cerrahpasa Cerrahpasa Tip Fakultesi
    Istanbul, 34098, Turkey (Türkiye)
  • Katip Celebi University Ataturk Training and Research Hospital
    Izmir, 35360, Turkey (Türkiye)
  • Kocaeli University Hospital
    Kocaeli, 41380, Turkey (Türkiye)
  • Namik Kemal Universitesi Sagli Uygulama ve Arastirma Hastanesi
    Süleymanpa?a, 59100, Turkey (Türkiye)
09

References and documents

Publications

  • Newsome SD, Krzystanek E, Selmaj KW, Dufek M, Goldstick L, Pozzilli C, Figueiredo C, Townsend B, Kletzl H, Bortolami O, Zecevic D, Giacobino C, Clinch S, Shen YA, Bhullar GD, Schneble HM, Centonze D. Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study. Neurology. 2025 May 13;104(9):e213574. doi: 10.1212/WNL.0000000000213574. Epub 2025 Apr 17. PubMed 40245351 ↗
  • Newsome SD, Goldstick L, Robertson DS, Bowen JD, Naismith RT, Townsend B, Figueiredo C, Kletzl H, Giraudon M, Bortolami O, Zecevic D, Giacobino C, Clinch S, Shen YA, Deol-Bhullar G, Bermel RA. Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study. Ann Clin Transl Neurol. 2024 Dec;11(12):3215-3226. doi: 10.1002/acn3.52229. Epub 2024 Oct 26. PubMed 39460719 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Mar 2023, 10 months.

Results were first posted in Aug 2026, 3 years 5 months after primary completion.

Of 20 phase 3 interventional studies under Multiple Sclerosis, Chronic Progressive, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 83. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2022
First posted
Feb 10, 2022
StartActual
May 3, 2022
Primary completionActual
Mar 10, 2023
CompletionActual
Jun 6, 2025
Results first posted
Aug 11, 2026
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05232825
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 10, 2022
Start date
May 3, 2022
Primary completion
Mar 10, 2023
Completion
Jun 6, 2025
Results posted
Aug 11, 2026
Last update
Aug 11, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocrelizumab

Start the discussion